Trial site
Azienda Socio Sanitaria Territoriale Ovest Milanese
Legnano, 20025, ItalyNot linked to an institution yet
- 20running trials
- 5closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 318 trials
- Phase 27 trials
- Phase 2/31 trial
- Status
- Recruiting11 trials
- Completed5 trials
- Not yet recruiting5 trials
- Active, not recruiting4 trials
- Suspended1 trial
- Lead sponsor
- AstraZeneca2 trials
- European Myeloma Network B.V.2 trials
- Spyre Therapeutics, Inc.2 trials
- AbbVie1 trial
- Agomab Spain S.L.U.1 trial
- and 18 more
Running trials
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Not yet recruiting
Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.
2025-523903-31-00· Phase 3· Fondazione IRCCS Istituto Nazionale Dei Tumori· Source
Not yet recruiting
triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
NCT07440381· Phase 3· Heart Care Foundation· Source
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
Confirmatory Clinical Study in Active Ulcerative Colitis
NCT07296315· Phase 2· MRM Health NV· Source
Recruiting
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690· Phase 2· Galderma R&D· Source
Recruiting
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· Phase 3· European Myeloma Network B.V.· Source
Recruiting
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
2024-515884-69-00· Phase 3· Gilead Sciences Inc.· Source
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· Phase 3· AstraZeneca· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· Phase 3· AstraZeneca· Source
Recruiting
Prospective comparative randomized study of procedural sedation during TAVR (Transcatheter Aortic Valve Replacement)
2024-511018-18-00· Phase 3· Azienda Socio Sanitaria Territoriale Ovest Milanese· Source
Recruiting
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)
2023-509551-14-00· Phase 3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Active, not recruiting
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841· Phase 3· AbbVie· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Active, not recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)
2022-500587-35-01· Phase 3· University Of Nottingham· Source
Active, not recruiting
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· Phase 3· Fondazione Italiana Linfomi - ETS· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error